^
Association details:
| Biomarker: | miR-503-5p overexpression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.
Published date:
05/19/2021
Excerpt:
miR-503-5p was significantly upregulated in the resistant MDA-MB-231R TNBC cell line when compared to its parental cell line MDA-MB-231 (̃3.5-fold; p< 0.0001). Then, gain/loss function assays showed that upregulation of miR-503-5p in MDA-MB-231 cells increased resistance to doxorubicin (p< 0.0001) and its downregulation in MDA-MB-231R cells had the opposite effect (p< 0.0001).
DOI:
10.1200/JCO.2021.39.15_suppl.1083